Navigation Links
MiMedx Group Announces Record First Quarter Results
Date:5/2/2012

ing expense associated with the debt discount recognized in connection with the senior secured promissory notes as compared to $0 in 2011. Interest expense for the three months ended March 31, 2012 was approximately $243,000 as compared to approximately $91,000 in the prior year.  The increase in reported interest expense of approximately $152,000 includes approximately $150,000 in coupon interest related to the $5M convertible promissory note, the convertible note with related party and the convertible debt related to the acquisition.Use of non-GAAP financial measuresManagement has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with GAAP. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company's on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies.

*Adjusted EBITDA is Earnings before interest, taxes, depreciation, amortization and share- based compensation. For a reconciliation of this non-GAAP financial measure to the most directly comparable financial measure, see accompanying table to this release. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Earnings CallMiMedx management will host a live broadcast of its first quarter of 2012 conference call on Wednesday, May 2, 2012, beginning at 10:30 a.m. eastern time.  A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at www.mimedx.com
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
5. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
6. MiMedx Announces Launch of AmnioFix™
7. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
8. MiMedx Group Announces 2010 Results
9. MiMedx Group Announces First Quarter 2011 Results
10. MiMedx Group, Inc. to Present at the Noble Financial Capital Markets Seventh Annual Equity Conference
11. MiMedx Group Completes $5,000,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)...  Eli Lilly and Company (NYSE: LLY ) ... therapies, reflecting Lilly,s diverse oncology pipeline, during the American ... April 18-22 in Philadelphia , Pa.  ... the theme of this year,s AACR meeting and one ... portfolio of therapies that accelerate the pace and progress ...
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading ... unaudited financial results for the fourth quarter and full ... 2014 Financial Highlights(Compared to the fourth quarter 2013) ... of 11.4% from $22.9 million in the prior year ... pandemic influenza vaccine of $0.1 million in the fourth ...
(Date:4/18/2015)... 18, 2015 Aurigene and ... will be presenting data at the poster sessions ... Cancer Research Annual Meeting (April 18-22 in ... (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene ... (NAMPT) small molecule inhibitors program, which is currently ...
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
Breaking Biology Technology:Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3
... Md., Oct. 4, 2011 Northwest Biotherapeutics (OTC.BB: ... be presenting at the second annual Cancer Immunotherapy: ... at the New York Academy of Medicine in ... opinion leaders, industry executives, and other stakeholders to ...
... LAFAYETTE, Ind., Oct. 4, 2011 Kylin Therapeutics, ... that it has received a notice of allowance ... for its second U.S. patent application. This newly ... as well as expanded areas on Kylin,s proprietary ...
... Oct. 4, 2011 Sequenom, Inc. (NASDAQ: ... analysis solutions, today announced the launch of its iPLEX ... associated with drug absorption, distribution, metabolism, and excretion (ADME). ... of pre-designed single nucleotide polymorphisms (SNP), insertions and deletions ...
Cached Biology Technology:NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 2NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 3NORTHWEST BIO Will Present at the Second Annual "Cancer Immunotherapy: A Long Awaited Reality Conference" at the New York Academy of Medicine, October 6, 2011 4Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology 2Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 2Sequenom Introduces iPLEX® ADME PGx Panel on MassARRAY® System 3
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... Conn. , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... new advertising campaign on CNBC television starting March 30 th ... will commence airing in New York ... Officer said: "We are excited about our new ad campaign ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... experiments with mice have found evidence that the body ... essential for healthy vision. , The finding may shatter ... called the retinal pigment epithelium, or RPE, is a ... of Investigative Ophthalmology & Visual Science. , RPE plays ...
... Clinic is testing a vaccine that enlists help from the ... The vaccine is designed to help smokers quit and to ... the investigational vaccine is being developed by Nabi Biopharmaceuticals to ... smoking. Normally when a smoker inhales, nicotine is carried by ...
... needing cancer treatment, can freeze mature, fertilized eggs, but ... for some this delay of treatment is not an ... somatic cells) can be preserved at any time but ... environment. , A team of scientists from Northwestern University ...
Cached Biology News:Bone marrow may restore cells lost in vision diseases 2Bone marrow may restore cells lost in vision diseases 3New technology addresses female fertility preservation 2
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Phospho-Cyclin D1 (Thr286) Antibody...
Biology Products: